Former President Joe Biden has delivered the first remarks since he announced he had an aggressive form of prostate cancer, speaking in a steady voice during a somber Memorial Day gathering and ...

Gen X, millennials are about three times more likely than their parents to be diagnosed with appendix cancer, study finds ...

En Memorial Sloan Kettering, atendemos a personas con todo tipo de cáncer y enfermedades relacionadas. Encuentre información detallada sobre nuestro enfoque de diagnóstico y tratamiento, médicos que ...

Results from the 17-year study by the University of Sydney and Canadian Cancer Trials Group found patients who undertook a three-year structured exercise program had a 37 per cent lower risk of ...

Early driver of prostate cancer aggressiveness Study links higher expression of the gene PROX1 to aggressive change in prostate tumor cells; FDA-approved class of drugs can disable PROX1 Date ...

The trial, in people treated for colon cancer, showed clear evidence that an exercise program lowered the risk of disease recurrence and death.

The announcement Sunday that former President Joe Biden was diagnosed with advanced prostate cancer has some people wondering how the disease could have been missed.

Former US President Joe Biden, 82, has been diagnosed with prostate cancer that has spread to his bones, a statement from his office said on Sunday. The discovery was made on Friday after he ...

Former President Joe Biden has been diagnosed with an "aggressive form" of prostate cancer that has spread to the bone, a spokesperson said in a statement on May 18. Biden, 82, was diagnosed on ...

Prostate cancer is cancer that starts in the prostate gland. The prostate gland is found at the base of the bladder and is about the size of a walnut.

Modified de Gramont is a drug combination of cancer drugs. It is used to treat bowel cancer. It may sometimes be used to treat other cancers. It may be given along with other cancer drugs Modified de ...

A previous phase 2 trial showed promising outcomes for patients with HER2-positive early-stage breast cancer using neoadjuvant de-escalation chemotherapy with paclitaxel, trastuzumab, and pertuzumab.